Development of stealth liposome coencapsulating doxorubicin and fluoxetine

References

• Abdul, M., Logothetis, C. J., Hoosein, N. M. (1995). Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154:247–250.
   PubMed Web of Science ®Google Scholar
• Abraham, S. A., Edwards, K., Karlsson, G., Hudon, N., Mayer, L. D., Bally, M. B. (2004). An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96:449–461.
   PubMed Web of Science ®Google Scholar
• Abraham, S A., Edwards, K., Karlsson, G., MacIntosh, S., Mayer, L. D., McKenzie, C., et al. (2002). Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565:41–54.
   PubMed Web of Science ®Google Scholar
• Abraham, S. A., Waterhouse, D. N., Mayer, L. D., Cullis, P. R., Madden, T. D., Bally, M. B. (2005). The liposomal formulation of doxorubicin. Meth Enzymol 391:71–97.
   PubMed Web of Science ®Google Scholar
• Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., et al. (2005). A phase I trial of liposomal doxorubicin, paclitaxel, and valspodar (PSC-833), an inhibitor of multidrug resistance. Ann Oncol 16:1968–1973.
   PubMed Web of Science ®Google Scholar
• Allen, C., Dos Santos, N., Gallagher, R., Chiu, G. N., Shu, Y., Li, W. M., et al. (2002). Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22:225–250.
   PubMed Web of Science ®Google Scholar
• Allen, T M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A. (1991). Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29–36.
   PubMed Web of Science ®Google Scholar
• Argov, M., Kashi, R., Peer, D., Margalit, R. (2009). Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 274:118–125.
   PubMed Web of Science ®Google Scholar
• Bangham, A. D., Standish, M. M., Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238–252.
   PubMed Web of Science ®Google Scholar
• Bartlett, G. R. (1959). Phosphorus assay in column chromatography. J Biol Chem 234:466–468.
   PubMed Web of Science ®Google Scholar
• Cainelli, F., Vallone, A. (2009). Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma. Biologics 3:385–390.
   PubMedGoogle Scholar
• Ceh, B., Lasic, D. D. (1997). A rigorous theory of remote loading of drugs into liposomes: transmembrane potential and induced pH-gradient loading and leakage of liposomes. J Coll Interf Sci 185:9–18.
   PubMed Web of Science ®Google Scholar
• Ceh, B., Winterhalter, M., Frederik, P. M., Lasic, D. (1997). Stealth liposomes: from theory to product. Adv Drug Deliv Rev 24:165–177.
   Web of Science ®Google Scholar
• Cheung, B. C., Sun, T. H., Leenhouts, J. M., Cullis, P. R. (1998). Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. Biochim Biophys Acta 1414(1–2):205–216.
   PubMed Web of Science ®Google Scholar
• Chou, T. C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621–681.
   PubMed Web of Science ®Google Scholar
• Coley, H. M. (2009) Mechanisms and consequences of chemotherapy resistance in breast cancer. European J Cancer Suppl 7:3–7.
   Google Scholar
• El-Dawy, M. A., Mabrouk, M. M., El-Barbary, F. A. (2002). Liquid chromatographic determination of fluoxetine. J Pharm Biomed Anal 30:561–571.
   PubMed Web of Science ®Google Scholar
• El Maghraby, G. M., Williams, A. C., Barry, B. W. (2005). Drug interaction and location in liposomes: correlation with polar surface areas. Int J Pharm 292(1–2):179–185.
   PubMedGoogle Scholar
• Fritze, A., Hens, F., Kimpfler, A., Schubert, R., Peschka-Suss, R. (2006). Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta 1758:1633–1640.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Goren, D., Cohen, R., Barenholz, Y. (1998). Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 53(1–3):275–279.
   PubMed Web of Science ®Google Scholar
• Hansen, M. B., Nielsen, S. E., Berg, K. (1989). Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Meth 119:203–210.
   PubMed Web of Science ®Google Scholar
• Haran, G., Cohen, R., Bar, L K., Barenholz, Y. (1993). Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151:201–215.
   PubMed Web of Science ®Google Scholar
• Harasym, T. O., Liboiron, B. D., Mayer, L. D. (2010). Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Meth Mol Biol 596:291–323.
   PubMedGoogle Scholar
• Harrigan, P R., Wong, K. F., Redelmeier, T. E., Wheeler, J. J., Cullis, P. R.. (1993). Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta 1149:329–338.
   PubMed Web of Science ®Google Scholar
• Hui, Y. H., Huang, N. H., Ebbert, L., Bina, H., Chiang, A., Maples, C., et al. (2007). Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs. J Pharmacol Toxicol Meth 56:256–264.
   PubMedGoogle Scholar
• Immordino, M. L., Dosio, F., Cattel, L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1:297–315.
   PubMed Web of Science ®Google Scholar
• Johnston, M. J., Edwards, K., Karlsson, G., Cullis, P. R. (2008). Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res 18:145–157.
   PubMed Web of Science ®Google Scholar
• Krishna, R., Mayer, L. D. (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR, and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265–283.
   PubMed Web of Science ®Google Scholar
• Krishnan, A., Hariharan, R., Nair, S. A., Pillai, M. R. (2008). Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol 75:1924–1934.
   PubMed Web of Science ®Google Scholar
• Lasic, D D., Ceh, B., Stuart, M. C., Guo, L., Frederik, P. M., Barenholz, Y. (1995). Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1239:145–156.
   PubMed Web of Science ®Google Scholar
• Li, X., Hirsh, D J., Cabral-Lilly, D., Zirkel, A., Gruner, S. M., Janoff, A. S., et al. (1998). Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1415:23–40.
   PubMed Web of Science ®Google Scholar
• Mayer, L. D., Harasym, T. O., Tardi, P. G., Harasym, N. L., Shew, C. R., Johnstone, S. A., et al. (2006). Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5:1854–1863.
   PubMed Web of Science ®Google Scholar
• Momo, F., Fabris, S., Stevanato, R. (2005). Interaction of fluoxetine with phosphatidylcholine liposomes. Biophys Chem 118:15–21.
   PubMed Web of Science ®Google Scholar
• Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Nagayasu, A., Uchiyama, K., Kiwada, H. (1999). The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 40(1–2):75–87.
   PubMed Web of Science ®Google Scholar
• Nielsen, D., Maare, C., Skovsgaard, T. (1996). Cellular resistance to anthracyclines. Gen Pharmacol 27:251–255.
   PubMedGoogle Scholar
• O’Brien, M. E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., et al. (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–449.
   PubMed Web of Science ®Google Scholar
• Peer, D., Dekel, Y., Melikhov, D., Margalit, R. (2004). Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 64:7562–7569.
   PubMed Web of Science ®Google Scholar
• Ranson, M. R., Cheeseman, S., White, S., Margison, J. (2001). Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit Rev Oncol Hematol 37:115–120.
   PubMed Web of Science ®Google Scholar
• Schuster, C., Fernbach, N., Rix, U., Superti-Furga, G., Holy, M., Freissmuth, M., et al. (2007). Selective serotonin reuptake inhibitors—a new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol 74:1424–1435.
   PubMed Web of Science ®Google Scholar
• Szoka, F., Olson, F., Heath, T., Vail, W., Mayhew, E., Papahadjopoulos, D. (1980). Preparation of unilamellar liposomes of intermediate size (0.1–0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta 601:559–571.
   PubMed Web of Science ®Google Scholar
• Tardi, P. G., Dos Santos, N., Harasym, T. O., Johnstone, S. A., Zisman, N., Tsang, A. W., et al. (2009). Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 8:2266–2275.
   PubMed Web of Science ®Google Scholar
• Tardi, P G., Gallagher, R. C., Johnstone, S., Harasym, N., Webb, M., Bally, M. B., et al. (2007). Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 1768:678–687.
   PubMed Web of Science ®Google Scholar
• Thomas, H., Coley, H. M. (2003). Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159–165.
   PubMedGoogle Scholar
• Thrivikraman, K. V., Huot, R. L., Plotsky, P. M. (2002). Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat. Brain Res Brain Res Protoc 10:84–94.
   PubMedGoogle Scholar
• Wang, J., Goh, B., Lu, W., Zhang, Q., Chang, A., Liu, X. Y., et al. (2005). In vitro cytotoxicity of stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 28:822–828.
   PubMed Web of Science ®Google Scholar
• Wang, J. C., Liu, X. Y., Lu, W. L., Chang, A., Zhang, Q., Goh, B. C., et al. (2006). Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Eur J Pharm Biopharm 62:44–51.
   PubMed Web of Science ®Google Scholar
• Zucker, D., Marcus, D., Barenholz, Y., Goldblum, A. (2009). Liposome drugs’ loading efficiency: a working model based on loading conditions and drug’s physicochemical properties. J Control Release 139:73–80.
   PubMed Web of Science ®Google Scholar